Recent advances in vaccination of non-responders to standard dose hepatitis B virus vaccine

World Journal of Hepatology

Volumn 7, Issue 24, 2015, Pages 2503-2509

  Walayat, Saqib ^a   Ahmed, Zohair ^a   Martin, Daniel ^a   Puli, Srinivas ^a   Cashman, Michael ^a   Dhillon, Sonu ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

Author keywords

Adjuvants; Hepatitis B vaccine; Intradermal vaccine; Non responders; Oral vaccine

Indexed keywords

EID: 84945912754     PISSN: None     EISSN: 19485182     Source Type: Journal    
DOI: 10.4254/wjh.v7.i24.2503     Document Type: Article

References (53)

1. World Health Organization. Hepatitis B. 2002. Available from: URL: http://apps.who.int/iris/handle/10665/67746
2. Kowdley KV, Wang CC, Welch S, Roberts H, Brosgart CL. Prevalence of chronic hepatitis B among foreign-born persons living in the United States by country of origin. Hepatology 2012; 56: 422-433 [PMID: 22105832 DOI: 10.1002/hep.24804]
3. FAQs for Health Professionals: Hepatitis B. Available from: URL: http://www.cdc.gov/hepatitis/HBV/HBVfaq.htm#overview 4 Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004; 11: 97-107 [PMID: 14996343 DOI: 10.1046/j.1365-2893.2003.00487.x]
4. Kane M. Global programme for control of hepatitis B infection. Vaccine 1995; 13 Suppl 1: S47-S49 [PMID: 7571830 DOI: 10.1016/0264-410X(95)80050-N]
5. Marion PL, Robinson WS. Hepadna viruses: hepatitis B and related viruses. Curr Top Microbiol Immunol 1983; 105: 99-121 [PMID: 6354611 DOI: 10.1007/9783-642-69159-1_2]
6. Shepard CW, Simard EP, Finelli L, Fiore AE, Bell BP. Hepatitis B virus infection: epidemiology and vaccination. Epidemiol Rev 2006; 28: 112-125 [PMID: 16754644 DOI: 10.1093/epirev/mxj009]
7. Poland GA, Jacobson RM. Clinical practice: prevention of hepatitis B with the hepatitis B vaccine. N Engl J Med 2004; 351: 2832-2838 [PMID: 15625334 DOI: 10.1056/NEJMcp041507]
8. Hyams KC. Risks of chronicity following acute hepatitis B virus infection: a review. Clin Infect Dis 1995; 20: 992-1000 [PMID: 7795104 DOI: 10.1093/clinids/20.4.992]
9. Levine OS, Vlahov D, Koehler J, Cohn S, Spronk AM, Nelson KE. Seroepidemiology of hepatitis B virus in a population of injecting drug users. Association with drug injection patterns. Am J Epidemiol 1995; 142: 331-341 [PMID: 7631637]
10. McQuillan GM, Coleman PJ, Kruszon-Moran D, Moyer LA, Lambert SB, Margolis HS. Prevalence of hepatitis B virus infection in the United States: the National Health and Nutrition Examination Surveys, 1976 through 1994. Am J Public Health 1999; 89: 14-18 [PMID: 9987458]
11. McAleer WJ, Buynak EB, Maigetter RZ, Wampler DE, Miller WJ, Hilleman MR. Human hepatitis B vaccine from recombinant yeast. Nature 1984; 307: 178-180 [PMID: 6318124]
12. Kim WR. Epidemiology of hepatitis B in the United States. Hepatology 2009; 49: S28-S34 [PMID: 19399791 DOI: 10.1002/hep.22975]
13. Chien YC, Jan CF, Kuo HS, Chen CJ. Nationwide hepatitis B vaccination program in Taiwan: effectiveness in the 20 years after it was launched. Epidemiol Rev 2006; 28: 126-135 [PMID: 16782778 DOI: 10.1093/epirev/mxj010]
14. Vora KA, Tumas-Brundage K, Manser T. Contrasting the in situ behavior of a memory B cell clone during primary and secondary immune responses. J Immunol 1999; 163: 4315-4327 [PMID: 10510371]
15. Bauer T, Jilg W. Hepatitis B surface antigen-specific T and B cell memory in individuals who had lost protective antibodies after hepatitis B vaccination. Vaccine 2006; 24: 572-577 [PMID: 16171909 DOI: 10.1016/j.vaccine.2005.08.058]
16. Gara N, Abdalla A, Rivera E, Zhao X, Werner JM, Liang TJ, Hoofnagle JH, Rehermann B, Ghany MG. Durability of antibody response against hepatitis B virus in healthcare workers vaccinated as adults. Clin Infect Dis 2015; 60: 505-513 [PMID: 25389254 DOI: 10.1093/cid/ciu867]
17. Koff RS. Immunogenicity of hepatitis B vaccines: implications of immune memory. Vaccine 2002; 20: 3695-3701 [PMID: 12399197 DOI: 10.1016/S0264-410X(02)00405-X]
18. Rubin LG, Levin MJ, Ljungman P, Davies EG, Avery R, Tomblyn M, Bousvaros A, Dhanireddy S, Sung L, Keyserling H, Kang I. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 2014; 58: e44-100 [PMID: 24311479 DOI: 10.1093/cid/cit684]
19. Godkin A, Davenport M, Hill AV. Molecular analysis of HLA class II associations with hepatitis B virus clearance and vaccine nonresponsiveness. Hepatology 2005; 41: 1383-1390 [PMID: 15915462 DOI: 10.1002/hep.20716]
20. Egea E, Iglesias A, Salazar M, Morimoto C, Kruskall MS, Awdeh Z, Schlossman SF, Alper CA, Yunis EJ. The cellular basis for lack of antibody response to hepatitis B vaccine in humans. J Exp Med 1991; 173: 531-538 [PMID: 1825504 DOI: 10.1084/jem.173.3.531]
21. Denis F, Mounier M, Hessel L, Michel JP, Gualde N, Dubois F, Barin F, Goudeau A. Hepatitis-B vaccination in the elderly. J Infect Dis 1984; 149: 1019 [PMID: 6234369]
22. de Rave S, Heijtink RA, Bakker-Bendik M, Boot J, Schalm SW. Immunogenicity of standard and low dose vaccination using yeast-derived recombinant hepatitis B surface antigen in elderly volunteers. Vaccine 1994; 12: 532-534 [PMID: 8036828 DOI: 10.1016/0264410X(94)90313-1]
23. Overton ET, Sungkanuparph S, Powderly WG, Seyfried W, Groger RK, Aberg JA. Undetectable plasma HIV RNA load predicts success after hepatitis B vaccination in HIV-infected persons. Clin Infect Dis 2005; 41: 1045-1048 [PMID: 16142673 DOI: 10.1086/433180]
24. Cruciani M, Mengoli C, Serpelloni G, Lanza A, Gomma M, Nardi S, Rimondo C, Bricolo F, Consolaro S, Trevisan M, Bosco O. Serologic response to hepatitis B vaccine with high dose and increasing number of injections in HIV infected adult patients. Vaccine 2009; 27: 17-22 [PMID: 18984022 DOI: 10.1016/j.vaccine.2008.10.040]
25. Mattos AA, Gomes EB, Tovo CV, Alexandre CO, Remião JO. Hepatitis B vaccine efficacy in patients with chronic liver disease by hepatitis C virus. Arq Gastroenterol 2004; 41: 180-184 [PMID: 15678203]
26. Gutierrez Domingo I, Pascasio Acevedo JM, Alcalde Vargas A, Ramos Cuadra A, Ferrer Ríos MT, Sousa Martin JM, Sayago Mota M, Giráldez Gallego A, Suárez Artacho G. Response to vaccination against hepatitis B virus with a schedule of four 40-μg doses in cirrhotic patients evaluated for liver transplantation: factors associated with a response. Transplant Proc 2012; 44: 1499-1501 [PMID: 22841195 DOI: 10.1016/j.transproceed.2012.05.071]
27. DaRoza G, Loewen A, Djurdjev O, Love J, Kempston C, Burnett S, Kiaii M, Taylor PA, Levin A. Stage of chronic kidney disease predicts seroconversion after hepatitis B immunization: earlier is better. Am J Kidney Dis 2003; 42: 1184-1192 [PMID: 14655190 DOI: 10.1053/j.ajkd.2003.08.019]
28. Agarwal SK, Irshad M, Dash SC. Comparison of two schedules of hepatitis B vaccination in patients with mild, moderate and severe renal failure. J Assoc Physicians India 1999; 47: 183-185 [PMID: 10999085]
29. Bonazzi PR, Bacchella T, Freitas AC, Osaki KT, Lopes MH, Freire MP, Machado MC, Abdala E. Double-dose hepatitis B vaccination in cirrhotic patients on a liver transplant waiting list. Braz J Infect Dis 2008; 12: 306-309 [PMID: 19030730]
30. Wiedmann M, Liebert UG, Oesen U, Porst H, Wiese M, Schroeder S, Halm U, Mössner J, Berr F. Decreased immunogenicity of recombinant hepatitis B vaccine in chronic hepatitis C. Hepatology 2000; 31: 230-234 [PMID: 10613751 DOI: 10.1002/hep.510310134]
31. Idilman R, De MN, Colantoni A, Nadir A, Van Thiel DH. The effect of high dose and short interval HBV vaccination in individuals with chronic hepatitis C. Am J Gastroenterol 2002; 97: 435-439 [PMID: 11866284 DOI: 10.1111/j.15720241.2002.05482.x]
32. Sangaré L, Manhart L, Zehrung D, Wang CC. Intradermal hepatitis B vaccination: a systematic review and meta-analysis. Vaccine 2009; 27: 1777-1786 [PMID: 19200451 DOI: 10.1016/j.vaccine.2009.01.043]
33. Jakob T, Udey MC. Epidermal Langerhans cells: from neurons to nature's adjuvants. Adv Dermatol 1999; 14: 209-258; discussion 259 [PMID: 10643500]
34. Glenn GM, Kenney RT, Hammond SA, Ellingsworth LR. Transcutaneous immunization and immunostimulant strategies. Immunol Allergy Clin North Am 2003; 23: 787-813 [PMID: 14753392 DOI: 10.1016/S0889-8561(03)00094-8]
35. Rahman F, Dahmen A, Herzog-Hauff S, Böcher WO, Galle PR, Löhr HF. Cellular and humoral immune responses induced by intradermal or intramuscular vaccination with the major hepatitis B surface antigen. Hepatology 2000; 31: 521-527 [PMID: 10655280]
36. Dhillon S, Moore C, Li SD, Aziz A, Kakar A, Dosanjh A, Beesla A, Murphy L, Van Thiel DH. Efficacy of high-dose intra-dermal hepatitis B virus vaccine in previous vaccination non-responders with chronic liver disease. Dig Dis Sci 2012; 57: 215-220 [PMID: 22160636 DOI: 10.1007/s10620-011-1996-0]
37. Barraclough KA, Wiggins KJ, Hawley CM, van Eps CL, Mudge DW, Johnson DW, Whitby M, Carpenter S, Playford EG. Intradermal versus intramuscular hepatitis B vaccination in hemodialysis patients: a prospective open-label randomized controlled trial in nonresponders to primary vaccination. Am J Kidney Dis 2009; 54: 95-103 [PMID: 19481320 DOI: 10.1053/j.ajkd.2009.03.010]
38. Wahl M, Hermodsson S. Intradermal, subcutaneous or intramuscular administration of hepatitis B vaccine: side effects and antibody response. Scand J Infect Dis 1987; 19: 617-621 [PMID: 3441747]
39. Hourvitz A, Mosseri R, Solomon A, Yehezkelli Y, Atsmon J, Danon YL, Koren R, Shouval D. Reactogenicity and immunogenicity of a new recombinant hepatitis B vaccine containing Pre S antigens: a preliminary report. J Viral Hepat 1996; 3: 37-42 [PMID: 8736239 DOI: 10.1111/j.13652893.1996.tb00079.x]
40. Bertino JS, Tirrell P, Greenberg RN, Keyserling HL, Poland GA, Gump D, Kumar ML, Ramsey K. A comparative trial of standard or high-dose S subunit recombinant hepatitis B vaccine versus a vaccine containing S subunit, pre-S1, and pre-S2 particles for revaccination of healthy adult nonresponders. J Infect Dis 1997; 175: 678-681 [PMID: 9041342 DOI: 10.1093/infdis/175.3.678]
41. Rendi-Wagner P, Shouval D, Genton B, Lurie Y, Rümke H, Boland G, Cerny A, Heim M, Bach D, Schroeder M, Kollaritsch H. Comparative immunogenicity of a PreS/S hepatitis B vaccine in non- and low responders to conventional vaccine. Vaccine 2006; 24: 2781-2789 [PMID: 16455169 DOI: 10.1016/j.vaccine.2006.01.007]
42. Zuckerman JN, Sabin C, Craig FM, Williams A, Zuckerman AJ. Immune response to a new hepatitis B vaccine in healthcare workers who had not responded to standard vaccine: randomised double blind dose-response study. BMJ 1997; 314: 329-333 [PMID: 9040320 DOI: 10.1136/bmj.314.7077.329]
43. Haubitz M, Ehlerding G, Beigel A, Heuer U, Hemmerling AE, Thoma HA. Clinical experience with a new recombinant hepatitis-B vaccine in previous non-responders with chronic renal insufficiency. Clin Nephrol 1996; 45: 180-182 [PMID: 8706359]
44. Jacques P, Moens G, Desombere I, Dewijngaert J, Leroux-Roels G, Wettendorff M, Thoelen S. The immunogenicity and reactogenicity profile of a candidate hepatitis B vaccine in an adult vaccine nonresponder population. Vaccine 2002; 20: 3644-3649 [PMID: 12399191 DOI: 10.1016/S0264-410X(02)00397-3]
45. Saade F, Honda-Okubo Y, Trec S, Petrovsky N. A novel hepatitis B vaccine containing Advax™, a polysaccharide adjuvant derived from delta inulin, induces robust humoral and cellular immunity with minimal reactogenicity in preclinical testing. Vaccine 2013; 31: 1999-2007 [PMID: 23306367 DOI: 10.1016/j.vaccine.2012.12.077]
46. Cooper C, Mackie D. Hepatitis B surface antigen-1018 ISS adjuvant-containing vaccine: a review of HEPLISAV™ safety and efficacy. Expert Rev Vaccines 2011; 10: 417-427 [PMID: 21506639 DOI: 10.1586/erv.10.162]
47. Akbar SM, Chen S, Al-Mahtab M, Abe M, Hiasa Y, Onji M. Strong and multi-antigen specific immunity by hepatitis B core antigen (HBcAg)-based vaccines in a murine model of chronic hepatitis B: HBcAg is a candidate for a therapeutic vaccine against hepatitis B virus. Antiviral Res 2012; 96: 59-64 [PMID: 22884884 DOI: 10.1016/j.antiviral.2012.07.011]
48. Lobaina Y, Hardtke S, Wedemeyer H, Aguilar JC, Schlaphoff V. In vitro stimulation with HBV therapeutic vaccine candidate Nasvac activates B and T cells from chronic hepatitis B patients and healthy donors. Mol Immunol 2015; 63: 320-327 [PMID: 25193323 DOI: 10.1016/j.molimm.2014.08.003]
49. Betancourt AA, Delgado CA, Estévez ZC, Martínez JC, Ríos GV, Aureoles-Roselló SR, Zaldívar RA, Guzmán MA, Baile NF, Reyes PA, Ruano LO, Fernández AC, Lobaina-Matos Y, Fernández AD, Madrazo AI, Martínez MI, Baños ML, Alvarez NP, Baldo MD, Mestre RE, Pérez MV, Martínez ME, Escobar DA, Guanche MJ, Cáceres LM, Betancourt RS, Rando EH, Nieto GE, González VL, Rubido JC. Phase I clinical trial in healthy adults of a nasal vaccine candidate containing recombinant hepatitis B surface and core antigens. Int J Infect Dis 2007; 11: 394-401 [PMID: 17257877 DOI: 10.1016/j.ijid.2006.09.010]
50. Batdelger D, Dandii D, Jirathitikal V, Bourinbaia AS. Open label trial of therapeutic hepatitis B vaccine V-5 Immunitor (V5) delivered by oral route. Lett Drug Des Discov 2007; 4: 540-544 [DOI: 10.2174/157018007782794545]
51. Buchmann P, Dembek C, Kuklick L, Jäger C, Tedjokusumo R, von Freyend MJ, Drebber U, Janowicz Z, Melber K, Protzer U. A novel therapeutic hepatitis B vaccine induces cellular and humoral immune responses and breaks tolerance in hepatitis B virus (HBV) transgenic mice. Vaccine 2013; 31: 1197-1203 [PMID: 23306359 DOI: 10.1016/j.vaccine.2012.12.074]
52. Cardell K, Akerlind B, Sällberg M, Frydén A. Excellent response rate to a double dose of the combined hepatitis A and B vaccine in previous nonresponders to hepatitis B vaccine. J Infect Dis 2008; 198: 299-304 [PMID: 18544037 DOI: 10.1086/589722]
53. Leroux-Roels G, Haelterman E, Maes C, Levy J, De Boever F, Licini L, David MP, Dobbelaere K, Descamps D. Randomized trial of the immunogenicity and safety of the Hepatitis B vaccine given in an accelerated schedule coadministered with the human papillomavirus type 16/18 AS04-adjuvanted cervical cancer vaccine. Clin Vaccine Immunol 2011; 18: 1510-1518 [PMID: 21734063]